Advanced Psychiatry Associates
Mental health clinic in Fairfield, California.
No reviews yet
View DetailsSpravato (Esketamine) in Fairfield, California
Compare 4 Spravato (Esketamine) clinics in Fairfield, California that offer care for treatment-resistant depression and major depressive disorder. Review services, ratings, and contact details to find the right provider near you.
Clinics
4 clinics shown
Kaiser Family Psychiatry
Kaiser Family Psychiatry provides outpatient psychiatric services at its Chadbourne Road location in Fairfield, serving Kaiser Permanente members in Solano County. The clinic offers psychiatric evaluations and medication management for adults with mood, anxiety, and other mental health conditions. Specific procedural treatments such as TMS or esketamine are not detailed in available listings; members should verify treatment availability through Kaiser's referral system or by contacting the clinic directly.
No reviews yetView DetailsMindful Health Solutions - Fairfield
Mental health clinic in Fairfield, California.
No reviews yetView DetailsNorth American Mental Health Services Fairfield
North American Mental Health Services operates an outpatient mental health clinic on Chadbourne Road in Fairfield, providing psychiatric evaluations and behavioral health treatment for adults. The practice offers general mental health services, though specific treatment modalities such as TMS, esketamine, or ketamine therapy are not detailed in available listings. Patients seeking information about particular treatment protocols should contact the clinic directly to confirm availability and eligibility requirements.
4.7(155)View Details
About Spravato (Esketamine)
Spravato is the brand name for esketamine, an FDA-approved nasal spray for treatment-resistant depression and major depressive disorder with suicidal ideation. It's derived from ketamine and works on the brain's glutamate system — a different mechanism than traditional antidepressants like SSRIs.
Treatment is administered only at REMS-certified clinics under direct medical supervision. Patients self-administer the spray under a clinician's guidance, then remain at the clinic for at least two hours of monitoring after each dose. The induction phase typically involves twice-weekly sessions for four weeks, followed by weekly or biweekly maintenance dosing depending on response.
Many patients report meaningful symptom improvement within the first one to two weeks — substantially faster than the 4 to 8 weeks typical of oral antidepressants. Spravato is taken alongside an oral antidepressant, not as a replacement.
The most common side effects are dissociation, dizziness, sedation, and elevated blood pressure during and shortly after dosing. These typically resolve within the two-hour monitoring window. Patients cannot drive on the day of treatment.
Most commercial insurance and Medicare cover Spravato for treatment-resistant depression with prior authorization. Clinics offering Spravato in our directory hold active REMS certification and are staffed to provide the required in-clinic monitoring period.